Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Beats Estimates By $0.23 EPS

Barinthus Biotherapeutics (NASDAQ:BRNS) posted its earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23, RTT News reports. The company had revenue of $14.97 million during the quarter. During the same quarter in the previous year, the company earned ($0.37) EPS.

Barinthus Biotherapeutics Price Performance

BRNS traded down $0.12 during trading on Friday, reaching $1.35. 43,853 shares of the stock were exchanged, compared to its average volume of 23,685. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.16. The business’s 50 day moving average price is $1.29 and its two-hundred day moving average price is $1.57. The company has a market capitalization of $53.22 million, a price-to-earnings ratio of -0.91 and a beta of -0.59.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BRNS shares. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a report on Friday. Alliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a research report on Tuesday, August 13th.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.